Hexagon Nutrition's growth story faces a director exit test
Strong FY26 results and 15-20% revenue guidance, but both directors sold all IPO shares — a governance gap the call left uncovered.
The numbers
- FY26 net profit surged 56% to ₹37.94 cr, on revenue of ₹382.63 cr.
- EBITDA margin rose to 13.83% from 12.33%, driven by higher-margin branded sales.
- Branded segment, at 60-68% gross margins, contributes 30% of revenue.
- Exports account for 50% of revenue; less than 20% goes to West Asia.
- Trade receivables jumped to ₹82 cr from ₹60 cr in Q4, attributed to a large ESG tender dispatch.
Management's story
- Guidance: 15-20% annual revenue growth for FY27, with margin gains expected.
- Clinical nutrition market pegged at ₹6,300 cr; company calls itself a 'small tip of the iceberg'.
- Priority growth brands are Pedia Gold and Obesigo, with tier-2/3 and e-commerce expansion.
- No significant capex planned; capacity buffer of 50-70% prioritises tender orders.
- Working capital spike is cyclical and normalised post Q4; order pipeline supports growth.
“The market size approximately is 6,300 crores for the clinical nutrition segment. So, we are still a small tip of the iceberg.”
— Management, Q&A
Where they diverge
The call painted a confident picture of sustained growth and market share gains, but did not address the complete IPO share divestment by both directors shortly after listing. That exit, reported in our prior coverage, is a governance red flag that management's narrative of long-term opportunity does not square with. Until that trust gap is closed, the earnings beat and guidance must be weighed against insider actions.
The full read
Hexagon Nutrition delivered a strong FY26: net profit up 56% to ₹37.94 cr, revenue ₹382.63 cr, and EBITDA margin rising to 13.83%. Management's maiden post-IPO call laid out a clear strategy—branded clinical nutrition expansion into tier-2/3 cities, e-commerce, and a 15-20% revenue growth target. The clinical nutrition TAM of ₹6,300 cr backs the narrative. But a governance gap undermines confidence: both directors sold all their IPO shares weeks after listing, a fact the call never mentioned. Management's confidence in maintaining growth momentum contrasts with that insider exit. For a stock at 29x trailing earnings, the growth story is priced in. The next test is whether the branded segment can deliver margin gains as guided, and whether the market trusts a management that has already cashed out.
What we're watching
- Q1 FY27 revenue growth versus 15-20% guidance (report due by August 2026).
- Branded segment revenue share: did it cross 30% in Q1?
- Trade receivables at end of Q1 FY27: did they revert below ₹70 cr as implied?
- Any further share transactions by promoters or directors (via exchange filings).